Guggenheim Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Yatin Suneja initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.
Guggenheim analyst Yatin Suneja initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.